Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript

Core Insights - Amicus is a rare disease-focused biotech company with three programs, each having a potential market opportunity of $1 billion, currently at different development stages [1] - The company is expected to turn profitable in the second half of the year and maintains a strong cash position [1] Product Performance - Galafold, the first approved product for Fabry disease, was launched in 2016 and is projected to achieve 10% to 15% growth this year, with sales exceeding $500 million [2] - Pombiliti, Opfolda, is in the early stages of its launch after receiving approval in 2023, indicating potential for future growth [2]